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Abstract: Endometriosis is a benign gynecological condition characterized by specific histological, 
molecular, and clinical findings. It affects 5%–10% of premenopausal women, is a cause of 
infertility, and has been implicated as a precursor for certain types of ovarian cancer. Advances 
in technology, primarily the ability for whole genome sequencing, have led to the discovery 
of new mutations and a better understanding of the function of previously identified genes and 
pathways associated with endometriosis associated ovarian cancers (EAOCs) that include PTEN, 
CTNNB1 (β-catenin), KRAS, microsatellite instability, ARID1A, and the unique role of inflam-
mation in the development of EAOC. Clinically, EAOCs are associated with a younger age at 
diagnosis, lower stage and grade of tumor, and are more likely to occur in premenopausal women 
when compared with other ovarian cancers. A shift from screening strategies adopted to prevent 
EAOCs has resulted in new recommendations for clinical practice by national and international 
governing bodies. In this paper, we review the common histologic and molecular characteristics 
of endometriosis and ovarian cancer, risks associated with EAOCs, clinical challenges and give 
recommendations for providers.
Keywords: clinical, molecular, pathways, inflammation, premenopausal
Introduction
Endometriosis is a benign gynecological condition that affects approximately 5%–10% 
of reproductive aged women causing symptoms of chronic pelvic pain, dyspareunia, 
dysmenorrhea, and infertility.1,2 Though endometriosis is a benign disease, it has 
features similar to that of malignant tumors including the ability to develop distant 
foci through proliferation, attachment, and invasion of the endometrial glandular 
epithelial tissue to distant organs.1,2 The most commonly affected organs include the 
ovaries, fallopian tubes, bladder, rectosigmoid colon, and myometrium, and it can be 
challenging to both identify and treat the condition due to great variability in the age 
of onset, response to treatment, and clinical presentation.2,3
In 1925, Sampson was the first to describe the relationship between endo-
metriosis and ovarian cancer and proposed a theory of malignant transformation of 
endometriosis.4 Czernobilsky and Morris later added to this theory by describing an 
“intermediate stage” in the malignant transformation called “atypical endometriosis”, 
which today is classified by the degree of dysplastic histologic atypia.5,6 Today it is 
thought that endometriosis is associated with 15%–50% of clear-cell and endometrioid 
ovarian tumors and there is a two- to three-fold increase in ovarian cancer in indi-
viduals with endometriosis.7–10 Modern research supports the concept of malignant 
transformation and the current consensus is that the histogenesis of endometriosis is 
multifactorial, combining genetic, hormonal, and immunological factors.
Recent advances in technology have allowed for further characterization of 
endometriosis associated ovarian cancers (EAOCs), leading to the identification of 
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genetic and molecular commonalities.3,11 Studies show that 
the endometriotic tissue has alterations in genes such as 
TP53, KRAS, and PTEN, in cellular pathways such as those 
regulated by microsatellites, and the immune microenviron-
ment, directly linked to the development of neoplasms.12–15 
Current research is focused on how these molecular changes 
have allowed for proliferation outside of the uterus and the 
ultimate transformation to EAOCs.
Here, we review the relationship between endometriosis 
and ovarian cancer, including common histologic and molec-
ular characteristics of endometriosis and ovarian cancer, the 
risks affiliated with EAOCs, and the clinical challenges we 
currently face (Tables 1 and 2).
Histologic and molecular 
characteristics of endometriosis 
and ovarian cancer
Epithelial ovarian cancer is divided into two subtypes: 
Type I and Type II. Each of these has a histological and 
molecular profile correlated with distinct clinical presenta-
tions, treatments, and survival outcomes.16 Type I tumors 
are slow growing and include low-grade serous carcinoma, 
mucinous carcinoma, endometrioid carcinoma, malignant 
Brenner tumor, and clear-cell carcinomas. Type II tumors are 
more aggressive and include high-grade serous carcinoma 
(moderately and poorly differentiated), malignant mixed 
mesodermal tumors (carcinosarcomas), and undifferentiated 
carcinoma.16
EAOCs represent a subclass of Type I ovarian neoplasms 
that primarily consist of endometrioid and clear-cell sub-
types with endometriosis found in 30%–55% of clear-cell 
and 30%–40% of endometrioid ovarian cancers.7,17–20 The 
current understanding of the molecular aspects of endo-
metriosis and EAOCs is that they carry distinct mutations in 
genes and pathways that distinguish them from non-EAOCs. 
These genes can be grouped into two categories: tumor sup-
pressor genes and oncogenes. The most commonly studied 
in EAOCs are tumor suppressor genes including TP53, 
Table 1 Clinical studies
Study (Year) Study type Sample 
size
Indication Outcome
Kwon et al82  
(2015)
Cost-effectiveness 
analysis
N/A Cost analysis of opportunistic  
salpingectomy for ovarian cancer  
prevention
Salpingectomy can be an effective and  
cost-efficient strategy for prevention  
of ovarian cancer
Kondi-Pafiti et al69  
(2012)
Case control 17 Investigation of clinical features  
associated with patients who have  
endometriosis and ovarian cancer
Clear-cell and endometrioid carcinomas  
presented earlier than serous carcinoma  
when associated with endometriosis
Wang et al18  
(2013)
Case control 226 explore differences between women  
with eAOC and typical epithelial  
ovarian cancer
Compared with non-eAOC, epithelial ovarian  
cancer plus endometriosis associated with:  
1) younger age and premenopausal at time of diagnosis;  
2) lower preoperative CA125; 3) earlier stage at 
identification; and 4) clear-cell and endometrioid carcinoma
Noli et al19 (2013) Case control 113 Assess survival patterns of patients  
with endometriosis plus ovarian  
cancer
Ovarian cancer plus endometriosis associated diagnosed 
at earlier stage; no association with survival
Qiu et al20 (2013) Case control 226 evaluate association between ovarian  
cancer and benign gynecologic  
conditions
endometriosis is associated with clear-cell and  
endometrioid carcinomas
Kumar et al73 
(2011)
Case control 126 Assessment of prognosis of ovarian  
cancer arising in endometriosis
eAOCs have better survival likely due to earlier stage  
and grade at diagnosis
Davis et al75 (2014) Case control 201 Comparisons of clinical and treatment 
outcomes in eAOCs and papillary  
serous tumors
eAOCs had higher rates of concurrent endometrial  
cancer and lower rate of recurrence but no difference  
in overall survival
Lim et al71 (2010) Retrospective 
cross-sectional
221 Investigation of clinical features  
of endometrioid ovarian cancer  
and coexistence of endometriosis
Dysmenorrhea and dyspareunia associated with both  
endometrioid ovarian cancer and endometriosis
Mangili et al72  
(2012)
Case control 65 Investigation of clinical and histologic  
features of eAOC subtype  
endometrioid
endometrioid subtypes of eAOC were associated with  
younger age, earlier stage, and higher rates  
of concurrent endometrial cancer at diagnosis
Boyraz et al86 
(2013)
Case control 1,086 evaluation of association between  
endometriosis and ovarian cancer
Ovarian cancer plus endometriosis associated with  
different histological subtypes, earlier presentation,  
and more favorable outcomes
Abbreviations: eAOCs, endometriosis associated ovarian cancers; N/A, not available.
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PTEN, and ARID1A while others include the oncogene 
KRAS.21,22 Recent investigation into pathways involved in 
the development of both endometriosis and ovarian cancer 
has provided valuable insight into the development of 
EAOCs, showing the similarities between the tumor-like 
inflammation profile of endometriosis and the gene expres-
sion of EAOCs.14,23
Tumor suppressors and EAOCs
Tumor suppressors are genes that code for proteins involved 
in cell cycle regulation and apoptosis. When both copies of 
this gene are mutated, abnormal cells are able to replicate out 
of control, leading to cancer.21 Tumor suppressor genes that 
have been identified as contributors to the development of 
EAOCs include TP53, PTEN, and ARID1A, which are found 
in 5%, 20%, and up to 50% of EAOCs, respectively.21,22
TP53 (locus 17p13.1) is one of the most well-studied 
tumor suppressor genes in cancer biology and encodes for 
nuclear protein p53.24 The role of the p53 protein is to identify 
abnormal or damaged cells, enhance cell cycle arrest and 
DNA repair, or induce apoptosis and senescence if repair 
is not possible.25 Mutations are related to an overexpression 
Table 2 Laboratory studies
Study (Year) Sample  
size
Indication Outcome
Suryawanshi et al14 
(2014)
120 Identification of genes and pathways involved  
in the inflammatory immunomodulation  
of endometriosis and eAOC
Complement pathways are prominently involved  
in both endometriosis and eAOCs
Wiegand et al22  
(2010)
665 Identification of genes involved in pathogenesis  
of endometriosis to eAOC
ARID1A mutated in ovarian clear-cell and endometrioid  
carcinomas
Govatati et al38  
(2013)
1,252 Assessment of PTEN mutations in eutopic and  
ectopic endometrial tissue in patients with 
endometriosis
PTEN somatic mutations are associated with 
endometriosis
Yamamoto et al35  
(2011)
79 PIK3CA mutations and transformation of  
endometriosis to eAOCs
PIK3CA mutation is an early event in the transformation  
of endometriosis to eAOCs
Rechsteiner et al32  
(2013)
142 Assessment of mutational profile of EAOC with  
focus on TP53, KRAS, and BRAF
TP53 found in advanced ovarian cancers; BRAF rare in  
eAOC; KRAS plus TP53 associated with mucinous eAOC
Nodin et al51 
(2013) 
163 Prognostic significance of KRAS mutation in  
epithelial ovarian cancer
KRAS mutations associated with well-differentiated and  
mucinous ovarian cancer; potential for increased survival  
in patients with KRAS mutations
Jones et al41 
(2010)
8 exploration of the genetics of ovarian clear-cell  
cancer
Frequent mutations in ARID1A in ovarian clear-cell  
cancers
Mao et al44 (2013) 246 Assessment of ARID1A mutation across tumor  
progression
ARID1A mutation associated with uterine endometrioid  
tumor progression
Jones et al42 
(2012)
759 Assessment of ARID1A mutation in various  
neoplastic diseases
ARID1A mutation not isolated to gynecological neoplasms
Guan et al45 
(2011)
75 Assessment of ARID1A mutation in various 
neoplastic diseases
ARID1A mutation associated with uterine endometrioid 
cancer
Burney et al23 
(2009)
4 Identification of differences in miRNA profiling  
of normal endometrium versus endometrium 
of women with endometriosis
MiR-9 was downregulated in endometrial tissue of 
women with endometriosis versus healthy individuals
Huang et al47 
(2013)
68 Attempt to correlate loss of ARID1A with other  
known mutations leading to eAOCs
ARID1A mutation is correlated with PI3K/Akt and  
ZNF217 alterations
McConechy et al52  
(2013)
306 Comparison of gene mutation frequencies in 
endometrial endometrioid and ovarian  
endometrioid carcinomas
PTEN gene increased in endometrial endometrioid  
carcinomas; CTNNB1 increased in ovarian endometrioid 
carcinomas
Liang et al54 (2012) Unknown Investigation of activation and inhibition of  
Wnt/β-catenin pathway in eutopic endometrium
Wnt/β-catenin signaling pathway involved in adhesion and 
invasion of eutopic endometrium in murine model
Matsuzaki and  
Darcha55 (2013)
70 Investigation of Wnt/β-catenin pathway in  
endometriosis associated fibrosis in murine model
Activation of pathway with recombinant Wnt led to  
prevention of progression of fibrosis
Suryawanshi et al15  
(2013)
68 evaluation of miRNAs as biomarkers for  
endometriosis and eAOC
miRNA expression patterns may serve as diagnostic  
biomarkers for discrimination of endometriosis and 
eAOC
Segev et al58 
(2013)
917 Investigation of risk factors between miRNA  
instability and ovarian cancers
No differences found in high versus low miRNA 
instability across ovarian cancer subtypes
Alves et al59 
(2013)
24 Investigation of miRNA patterns, instability, and  
correlation with histology of ovarian cancer
miRNA instability is less common than other mutations  
in ovarian cancer
Abbreviations: eAOCs, endometriosis associated ovarian cancers; miRNA, microRNA.
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of the nonfunctional form that causes an accumulation of 
the protein in the nuclei of cells.24,26,27 Mutations in p53 are 
important precursors in ovarian cancer with some studies 
suggesting its presence in up to 50% of advanced stage 
ovarian carcinomas.24,28 However, controversy exists over its 
involvement in Type I ovarian tumors with high estimates of 
10% in clear-cell and 30% in endometrioid ovarian cancers 
and low estimates of 5% in all Type I ovarian tumors.24 Early 
studies examining the role of TP53 in the transformation 
of endometriosis to carcinoma found mutations associated 
with severe/late stage endometriosis. Statistically significant 
changes in the rates of p53 expression in the transition from 
typical to atypical endometriosis have also been observed 
with the accumulation of the p53 protein found in endometri-
osis adjacent to clear-cell and endometrioid carcinomas.9,29,30 
However, many of these studies had very small sample sizes 
and did not demonstrate statistically significant differences 
in these associations.
More recently, it has been suggested that p53 mutations 
exist in most of the Type II tumors and only in advanced 
Type I ovarian tumors. It is now most commonly associated 
with high-grade serous ovarian cancer and advanced ovar-
ian cancers, with 92%–96% of these tumors expressing a 
mutation in this tumor suppressor gene.28,31,32 With a growing 
body of evidence supporting that p53 mutations are more 
often associated with non-EAOCs, there has been a decrease 
in focus on p53 and its involvement in the transition from 
endometriosis to EAOCs.
In contrast to the lack of supporting evidence for p53, 
PTEN, a tumor suppressor gene first identified by Sato et al 
in 2000, has continued to show involvement in the malignant 
transformation of endometriosis to ovarian cancer in up to 
20% of EAOC. Initial studies found mutations leading to 
the inactivation and loss of heterozygosity of PTEN (locus 
10q23.3) that were associated with endometrioid and clear-
cell carcinomas in both endometrial and ovarian cancers.13,33,34 
Mutations of PTEN have been found in benign ovarian endo-
metrioid cysts and studies show that the same mutations in 
PTEN can be found concurrently in both the ovarian cancer 
and adjacent endometriosis.13,35 Further characterization of 
the PTEN pathway found that the PTEN mutation is involved 
in the PI3K signaling pathway with a loss of heterozygos-
ity, resulting in the activation of PI3K and leading to the 
development of clear-cell subtypes of EAOCs.35,36 Addi-
tionally, mouse models have shown that concomitant PI3K/
PTEN and Wnt signaling pathways are sufficient to induce 
EAOCs.37 Recent research by Govatati et al38 has further 
characterized the transformation of endometriosis to EAOCs. 
The authors demonstrated increased mutations in PI3K/PTEN 
and the downstream target, Akt, in the eutopic endometrial 
tissue of patients with endometriosis, suggesting that the 
initial mutations occur in eutopic endometrial cells and 
subsequently migrate out to become an ectopic tissue (endo-
metriosis). There are ongoing studies on the characterization 
of the downstream effects of PTEN mutations with clinical 
studies suggesting that PTEN overexpression can enhance 
the antitumor effects and even reverse the resistance of some 
chemotherapeutic drugs.39,40
As technology advanced, the capacity to perform 
genome-wide analyses and the opportunity for whole 
exome and RNA sequencing to assess somatic mutations in 
ovarian cancer have developed. In 2010, two independent 
studies revealed that somatic mutations in ARID1A were 
major molecular contributors to clear-cell and endometrioid 
ovarian cancers.22,28,41 Subsequent research has shown that 
the ARID1A mutation is present in approximately 50% of 
clear-cell and 40% of endometrioid ovarian cancers.41,42 
The majority of ARID1A mutations are either frameshift or 
nonsense, suggesting its role as a tumor suppressor gene. 
The protein it encodes, BAF250a, is part of a multiprotein 
SWI/SNF chromatin remodeling complex involved in the 
regulation of cellular processes including differentiation, 
proliferation, DNA repair, and tumor suppression.43,44 In 
a study of EAOCs, Wiegand et al found 73% of clear-cell 
and 50% of endometrioid ovarian cancers with an ARID1A 
mutation have a loss of expression of BAF250a compared 
to approximately 10% of non-EAOCs. They confirmed this 
relationship with immunohistochemical studies where they 
found that silencing of ARID1A resulted in a loss of BAF250a 
expression.22 Further investigation has found specimens 
where ARID1A was mutated in both the ovarian tumor and 
adjacent endometriosis, providing support for its involvement 
in the progression of endometriosis to carcinoma.
In addition to the role in ovarian cancer, loss of ARID1A 
has also been demonstrated in 26% of uterine endometrioid 
carcinomas and has been found to correlate with uterine 
endometrioid tumor progression from low grade to high 
grade.44,45 Although somatic ARID1A mutations are found 
in many gynecological cancers, it appears to be isolated to 
EAOCs and endometrioid uterine cancers.42,46
Current research is focused on correlating ARID1A muta-
tions with other mutations in the EAOCs and ARID1A poten-
tial for use as a prognostic factor for malignant neoplasms. 
Huang et al recently reported that ARID1A mutations coincide 
with the activation of the PI3Kc-Akt pathway that has been 
identified in ovarian clear-cell carcinomas.47
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Loss of ARID1A has not yet been identified as a prognos-
tic factor in ovarian cancer; however, preliminary research 
in breast cancer has suggested that the absence of BAF250a 
is associated with poorer postoperative disease survival and 
suggests that it may be useful as a target for breast cancer 
treatment.48
Genetic changes in EAOCs
While the genes coding for tumor suppressors account 
for many of the mutations involved in the development of 
EAOCs, other dysregulations in both genes and cell cycle 
pathways have been implicated in the development of these 
diseases.
Oncogenes and cell pathways
Oncogenes are mutant gene forms that when activated con-
tribute to the development of cancer by causing uncontrolled 
cellular growth and division. KRAS is an oncogene that 
encodes a GTPase transducer protein involved in regulating 
cell division by relaying external signals to the cell nucleus. 
KRAS mutations disrupt the ability of the GTPase transducer 
protein to switch between active and inactive forms leading to 
dysregulated cell proliferation.49 Mutations have been found 
to occur in 3.7%–36.4% of endometrioid cancers, with most 
studies suggesting a mutation rate of approximately 10%.34 
A mouse model comparing the activation of KRAS in endo-
metrial cells deposited in the peritoneum to the activation of 
KRAS in peritoneal cells showed that the KRAS and PTEN 
mutations concurrently progressed to endometrioid ovarian 
cancer.32,34 However, recent evidence suggests that although 
mutations in KRAS occur in both endometrioid and clear-cell 
ovarian tumors, they appear to be most prevalent in muci-
nous, low grade, and well-differentiated ovarian cancers.50,51 
Further studies are warranted to determine whether prognosis 
is impacted by the presence of KRAS, as some research has 
suggested that survival may be increased in patients with 
this mutation.51
Another gene involved in the regulation of the cell 
cycle, CTNNB1, is the gene that encodes the β-catenin 
protein involved in the Wnt/β-catenin pathway and regula-
tion of cellular processes including proliferation, motility, 
and survival.37 It is found in up to 40% of endometrioid 
ovarian carcinomas and both accumulation and depletion of 
β-catenin may be associated with dysregulation, leading to 
malignancy.52,53 CTNNB1 has been associated with squamous 
differentiation, low tumor grade, and a good prognosis in 
endometrioid ovarian cancers.31,52 Recent in vivo murine 
models have shown that alterations in the Wnt/β-catenin 
signaling pathway promote eutopic endometrial cell invasion 
and adhesion, providing evidence for the involvement of this 
pathway in the transformation of endometriosis to ovarian 
cancer.54 Another study investigated the effects of the signal-
ing pathway in the mechanism of endometriosis associated 
fibrosis and reported that the activation of the Wnt/β-catenin 
pathway by treatment with recombinant Wnt led to the pre-
vention of fibrosis associated with endometriosis.55
miRNA
miRNAs are endogenous 22-nucleotide-long, highly con-
served, noncoding RNAs thought to be primarily involved in 
the negative regulation of target genes in cell cycle progres-
sion, proliferation, and differentiation.23 Studies on miRNA 
expression have shown downregulation of specific miRNAs 
in clear-cell and endometrioid ovarian cancers, decreased 
expression in recurrent versus primary ovarian cancers, and 
up to 25-fold reductions in moderate-to-severe endometriosis 
when compared to normal endometrium.23,56,57 miRNA pro-
filing in the plasma of healthy individuals compared to that 
of individuals with endometriosis and ovarian cancer found 
that novel miRNA markers could distinguish between these 
groups with good sensitivity and specificity.15,23 However, 
subsequent studies comparing expression of high, low, or 
stable microsatellite instability have failed to find any dif-
ferences that can distinguish between specific histologic sub-
types of ovarian cancers or provide prognostic value.58,59
Microsatellite instability
Microsatellite instability is defined as a size change in short 
tandem repeat sequences in a tumor compared to normal 
tissue of the same patient, reflecting the inactivation of the 
mismatch repair genes. This alteration has been implicated 
in 7%–22% of sporadic ovarian cancers and is commonly 
associated with the BRCA1 or BRCA2 germ-line mutations 
found in inherited ovarian cancers.60,61
Inflammation and the immune 
system
The role of inflammation in the development of cancers is 
well known, but in the case of EAOCs it may be of particular 
relevance. Endometriosis is the site of local inflammatory 
reactions that are associated with an increase in cytokines 
and growth factors, leading to angiogenesis, dysregulation 
of cellular proliferation and apoptosis, invasion, metastasis, 
and reactive oxygen species known for their damage to 
DNA.27 This inflammation is thought to promote the growth 
and invasion of endometriotic tissue, possibly contributing 
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to the histological change from benign endometriosis 
to what is known as an intermediate stage or “atypical” 
endometriosis.62 Atypical endometriosis is characterized by 
large, pleiomorphic nuclei, increased nuclear-to-cytoplasmic 
ratio, cellular crowding, stratification, and tufting of cells.14 
With 60%–80% of EAOCs found to be associated with 
atypical endometriosis, efforts have been made to better 
understand the role of inflammation and its contribution 
to the immune microenvironment. Studies have shown 
that the peritoneal fluid of women with endometriosis has 
increased levels of pro-inflammatory cytokines and growth 
factors such as TNF-α, IL-1, and IL-6 and have serum pro-
files of inflammatory markers comparable to those found 
in women with ovarian cancer.63,64 Furthermore, when 
both eutopic and ectopic endometrial tissue were exposed 
to upregulators of the inflammatory response, the ectopic 
tissue was 100 times more sensitive, suggesting a much dif-
ferent molecular profile than its eutopic counterpart.65 Most 
recently, the evaluation of the tissue immune microenviron-
ment has revealed a specific role for complement proteins 
in the malignant transformation of endometrial tissue.14 
Suryawanshi et al demonstrated that when the KRAS and 
PTEN pathways were activated, upregulation of complement 
proteins in epithelial cells were observed. They also found 
that different immune “profiles” exist for each of eutopic 
endometrium, endometriotic tissue, and EAOCs. Because 
of the sensitivity and specificity these immune profiles have 
for detecting early molecular changes in cells undergoing 
malignant transformation, it is possible that immune system 
profiling could lead to early detection of women at risk for 
EAOCs.14 Continued research into inflammation and the 
role of the immune system in the development of endo-
metriosis and EAOCs is underway and represents exciting 
possibilities for new management and treatment strategies 
of these diseases.
Risks associated with endometriosis 
and EAOCs
Despite the evidence to support the malignant transformation 
of endometriosis, the risk of developing an ovarian carcinoma 
from endometriosis is relatively low with frequencies cited 
between 0.3% and 0.8%.66,67 However, with endometriosis 
affecting approximately 10%–15% of all premenopausal 
women and from 30% to 50% of women with a diagnosis of 
infertility, it is important to understand the clinical character-
istics of EAOCs in an attempt to provide earlier diagnosis and 
more targeted treatments, and develop prevention strategies 
for these women.3,68
EAOCs represent a subclass of Type I ovarian neoplasms 
primarily including endometrioid and clear-cell histology. They 
have unique clinical characteristics that include age at time of 
diagnosis, International Federation of Gynecology and Obstet-
rics (FIGO) stage, CA125 levels, and survival outcomes.69
Age at diagnosis
Studies indicate that at the time of diagnosis, patients who 
are diagnosed with EAOC are younger, present at an earlier 
stage, and have a lower grade tumor than those with other 
ovarian carcinomas.17,18,70,71 One recent study found that 
patients diagnosed with EAOCs were 6 years younger and 
35% more likely to be premenopausal than women with other 
ovarian cancers. This notion was further supported by Mangili 
et al who found that the average age at diagnosis for women 
with EAOCs was 55 years while the average age of women 
diagnosed with non-EAOCs was 62 years (P=0.03).72
Stage at diagnosis
FIGO stage and grade of ovarian cancer are significantly cor-
related with 5-year survival rates in ovarian cancer and there 
is strong evidence to suggest EAOCs are more likely to be 
diagnosed at both an earlier stage and lower grade53,54 Wang 
et al18 stated that 88.2% of EAOCs were diagnosed at Stage I 
versus 15.8% of non-EAOCs. Kumar et al73 found 49% to be 
FIGO I or II; and Erzen et al74 reported that 67% of EAOCs 
were diagnosed at Stage I versus 27.6% for non-EAOCs. 
Similarly, grade I/II tumors were found more commonly in 
patients who had EAOCs than in those who had other ovarian 
tumors.18,75 Earlier grade and stage in ovarian cancer predict 
increased survival at 5 years; thus the diagnosis of an EAOC 
could mean better clinical outcomes for patients. Davis et al 
recently compared clinical outcomes of the most common 
type of ovarian tumor, papillary serous, and outcomes of 
EAOCs.75 The results showed that compared to papillary 
serous subtypes, EAOCs were associated with an earlier stage 
(I/II), lower grade and younger age at time of diagnosis, as 
well as a lower rate of recurrence.
As reviewed above, most studies confirm that EAOCs are 
associated with younger ages, earlier stages, and lower grades 
at diagnosis. However, despite these seemingly beneficial 
prognostic factors, research has not demonstrated a difference 
in 5-year survival rates between patients with EAOCs and 
non-EAOCs when stage was controlled.18,19,72,75
Concurrent cancers at diagnosis
One identified risk for women diagnosed with EAOC is the 
increased incidence of concurrent malignancy at the time of 
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diagnosis. In up to 10% of women diagnosed with EAOCs, 
a secondary cancer diagnosis has been made.76 Davis et al 
found that 23.8% of EAOCs had a concurrent primary cancer 
diagnosis and that 94.1% were endometrial cancer.75 This 
finding was replicated by Mangili et al who reported that 
40% of patients with EAOCs also had a diagnosis of endo-
metrial cancer.72 Furthermore, of these patients, 33% of them 
had an endometrioid EAOC subtype and 94% had the same 
histology in both the ovarian and uterine malignancy. This 
relationship between EAOCs and endometrial cancer has led 
to much debate over the molecular mechanisms that dictate 
the transformation of endometriosis to ovarian cancer.
Screening for endometriosis 
and EAOCs
Because an earlier stage at diagnosis of ovarian cancer is 
associated with a better prognosis, women diagnosed with 
endometriosis represent a unique population that could 
benefit from a reliable screening tool that helps in earlier 
diagnosis and treatment. CA125 is a marker used in the 
surveillance of ovarian tumors and has a high sensitivity, 
but poor specificity for diagnosis of ovarian cancers. Its 
relationship in EAOCs has been studied and results are con-
troversial. A recent study by Wang et al18 found that patients 
with EAOCs had significantly lower levels of presurgical 
CA125 (122.9 vs 1,377.5). In contrast, most other studies 
have found no significant difference between patients with 
EAOCs and non-EAOCs.17,71,72,75
Though molecular advancements have allowed for the 
identification of unique immune profiles, these have yet to 
be validated in the clinical setting. Ongoing efforts continue 
with a goal of identifying markers that can reliably predict if 
a woman with endometriosis is at a high risk for the develop-
ment of an EAOC.
Conclusion
Over the last several decades, technology has advanced 
and allowed for further characterization of the link between 
endometriosis and EAOCs. Genetic profiling has defined 
two main categories of epithelial ovarian cancers: Type I 
and Type II. Type I tumors are the focus of this review 
and include the less aggressive endometrioid and clear-cell 
histologies, associated with low-grade, earlier stage at diag-
nosis and, as some studies suggest, better overall prognosis. 
Evidence exists to support a unique etiology of these tumors 
compared to other types of ovarian cancers. Specifically, 
these tumors are thought to arise as a result of mutations 
in genes and pathways involved in cell signaling including 
molecules such as PTEN, ARID1A, and KRAS as well as the 
CTNNB1 signaling pathway of benign endometriotic tissue. 
These mutations cause histologic changes that lead to what 
is thought to be the intermediary stage known as atypical 
endometriosis and finally to the malignant form of EAOC.31 
Though this theory is supported by strong research, we do 
not yet have conclusive evidence to say that endometriosis 
is definitively the precursor to EAOCs.
While efforts continue to focus on solidifying this theory, 
other areas of research include the development of preven-
tion strategies. Though we have not yet found a reliable 
method to screen for ovarian cancer, research into prevention 
strategies are promising and provide further insight into the 
pathogenesis of ovarian cancer.
Two predominant theories surrounding the location of 
initial malignant transformation of endometrial cells lead-
ing to EAOCs have been established. One theory suggests 
that invasive endometriosis leading to ovarian carcinoma 
results from phenotypically normal endometrial cells that 
are displaced into the pelvis by retrograde menstrual flow 
and develop the adhesive and proliferative properties of 
endometriosis. Over time, these cells acquire the mutations 
discussed above and become invasive subsequently leading 
to ovarian cancer. Another theory proposes that the inciting 
event is the mutation in eutopic endometrium that allows for 
endometrial cell migration through the fallopian tubes and 
proliferation outside of the uterus resulting in an invasive 
endometriosis phenotype and subsequent carcinoma. This 
theory is supported by molecular differences originally 
thought to be isolated to endometriotic tissue, but were later 
found to also be present in eutopic endometrial tissue of 
women with endometriosis and absent in endometrial tissue 
of disease-free women.2,77
Both the above theories propose an endometrial origin 
of the cells of EAOC that has been most convincingly 
supported through evidence collected from research into 
prevention strategies. It is well established that the use of 
combined oral contraceptives for at least 5 years can reduce 
the risk of developing ovarian cancer by up to 50%.78 One 
of the main reasons for this protective effect was thought to 
be the reduction in the number of ovulatory cycles over a 
woman’s lifetime.
However, other theories have proposed that it is a thicken-
ing of the cervical mucosa that prevents an influx of inflam-
matory agents leading to the damage of cells that protects 
against ovarian cancer.79 This latter idea is supported by 
evidence from studies such as the large meta-analysis by Sieh 
et al demonstrating a 50% risk reduction in both clear-cell 
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and endometrioid ovarian cancers with tubal ligation by all 
methods.80
Recently, an emerging body of evidence exists to suggest 
that the removal of the distal one-third of the fallopian tube 
significantly reduces a woman’s chance of developing ovar-
ian cancer.81 Though the idea that most ovarian cancers actu-
ally originate from the fallopian tube was first postulated in 
1896 by Alban Doran, new research is supporting a return to 
the idea that many of the cancers thought to originate from the 
ovary are actually of fallopian tube origin. With this in mind, 
it has been proposed that by removing the tube, the connection 
between the uterus and the peritoneal cavity, the pathway for 
endometriotic tissue and carcinogenic inflammants leading 
to the development of ovarian cancer is eliminated.
A collaborative effort from the British Columbia Ovarian 
Cancer Research Group operating out of Canada has been 
one of the biggest research and educational proponents of 
what is known as the “opportunistic salpingectomy” for 
prevention of ovarian cancer.82 This procedure, described as 
the removal of fallopian tubes in a woman undergoing pelvic 
surgery for another indication, is supported by initial studies 
that project the reduction in ovarian cancer by this strategy 
alone to be up to 40%.82,83 If this continues to be supported, 
then careful contraceptive counseling and efforts to remove 
fallopian tubes during appropriate procedures by providers 
can help to reduce the incidence of ovarian cancers, including 
EAOCs, by preventative methods. Governing bodies, includ-
ing the American College of Obstetrics and Gynecology and 
the Society of Gynecology Oncology, currently endorse that 
risk-reducing salpingectomy should be discussed at the time 
of abdominal or pelvic surgery, hysterectomy, or lieu of tubal 
ligation.84,85 Further studies on the long-term effects of these 
recommendations are underway and it will be interesting 
to see how this new strategy contributes to the knowledge 
of both pathogenesis of ovarian cancer and methods in the 
prevention and protection against this disease.
In conclusion, we have made great strides in our under-
standing of the association between endometriosis and 
EAOCs. Through characterization of what was at one time 
thought to be two independent diseases, we have now proven 
that endometriosis may be the precursor for Type I epithe-
lial ovarian cancers. Women with endometriosis should be 
considered at an increased risk for the development of ovarian 
cancer and providers should pay close attention to changes 
or worsening of symptoms. Furthermore, major governing 
bodies support new recommendations for prevention strate-
gies of ovarian cancer through opportunistic salpingectomy 
and attempts should be made to adopt these into clinical 
practice. Future research should attempt to answer why only 
some patients with endometriosis over time will develop an 
EAOC and how we can identify this subgroup of patients. Our 
challenge is to continue to build on current research leading 
to future discoveries that will help us to understand enough 
about ovarian cancer so that we can significantly reduce the 
morbidity and mortality associated with this disease.
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